Literature DB >> 20645920

Modulators of multidrug resistance associated proteins in the management of anticancer and antimicrobial drug resistance and the treatment of inflammatory diseases.

An-Kui Yang1, Zhi-Wei Zhou, Min Qian Wei, Jun-Ping Liu, Shu-Feng Zhou.   

Abstract

Human multidrug resistance protein (MRP/ABCC) family contains 9 members (MRP1-9) which transport a structurally diverse array of anticancer and antimicrobial drugs and several important endogenous substances including prostaglandins (PGs) and leukotrienes (LTs) with different substrate specificity. MRP1-5 can collectively confer resistance to natural product anticancer drugs and their conjugated metabolites, platinum compounds, folate antimetabolites, nucleoside and nucleotide analogs, and alkylating agents. MRP1-3 are often associated with tumor resistance which is often caused by an increased efflux and decreased intracellular accumulation of natural product anticancer drugs and other anticancer agents. Both PGE(1) and PGE(2) are known high-affinity substrates of MRP4, but not MRP1, MRP2, MRP3 and MRP5. LTC(4) is a substrate of MRP1, MRP2, MRP3, and MRP6-8. MRP2 is also able to transport LTD(4) and LTE(4). Experimental studies in Abcc1-difficient mice have demonstrated a role of MRP1 in inflammation process in vivo. Abcc3-difficient mice have normal bile salt transport, however they have decreased blood bilirubin glucuronide levels. Abcc6-difficient mice show remarkable mineraliztion of the connective tissues, including skin, arterial blood vessels, and retina. Most MRP/ABCC transporters are subject to inhibition by a variety of compounds. Drug targeting of these transporters to overcome MRP/ABCC-mediated multidrug resistance may play a role in cancer and infection (e.g. HIV infection) chemotherapy. Some modulators of MRPs have shown reversing effects on MDR phenotype in preliminary clinical studies and some modulators of MRPs may modify the inflammatory process and consequently ameliorate the inflammatory symptoms. A better understanding of the interactions of these modulators with MRPs has important implications in development of novel drugs for treatment of cancer, infection and inflammation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20645920     DOI: 10.2174/156802610792928040

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  8 in total

1.  Urethral dysfunction in a rat model of chemically induced prostatic inflammation: potential involvement of the MRP5 pump.

Authors:  Eduardo C Alexandre; Nailong Cao; Shinsuke Mizoguchi; Tetsuichi Saito; Masahiro Kurobe; Daisuke Gotoh; Meri Okorie; Taro Igarashi; Edson Antunes; Naoki Yoshimura
Journal:  Am J Physiol Renal Physiol       Date:  2020-02-10

2.  Comprehensive metabolome analysis for the pharmacological action of inchinkoto, a hepatoprotective herbal medicine.

Authors:  Hiromasa Yamashita; Katsuya Ohbuchi; Masato Nagino; Tomoki Ebata; Kazuaki Tsuchiya; Hirotaka Kushida; Yukihiro Yokoyama
Journal:  Metabolomics       Date:  2021-12-02       Impact factor: 4.290

3.  Efflux protein expression in human stem cell-derived retinal pigment epithelial cells.

Authors:  Kati Juuti-Uusitalo; Hanna Vaajasaari; Tuomas Ryhänen; Susanna Narkilahti; Riitta Suuronen; Eliisa Mannermaa; Kai Kaarniranta; Heli Skottman
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

4.  Siva‑1 regulates multidrug resistance of gastric cancer by targeting MDR1 and MRP1 via the NF‑κB pathway.

Authors:  Fan-Biao Kong; Qiao-Ming Deng; Hong-Qiang Deng; Chen-Cheng Dong; Lei Li; Chun-Gang He; Xiao-Tong Wang; Sheng Xu; Wei Mai
Journal:  Mol Med Rep       Date:  2020-06-03       Impact factor: 2.952

Review 5.  Cell Migration Related to MDR-Another Impediment to Effective Chemotherapy?

Authors:  Jakub Kryczka; Joanna Boncela
Journal:  Molecules       Date:  2018-02-05       Impact factor: 4.411

Review 6.  Traditional Chinese Medicine Therapy for Esophageal Cancer: A Literature Review.

Authors:  Luchang Cao; Xinmiao Wang; Guanghui Zhu; Shixin Li; Heping Wang; Jingyuan Wu; Taicheng Lu; Jie Li
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

Review 7.  Drug resistance: from bacteria to cancer.

Authors:  Harsh Patel; Zhuo-Xun Wu; Yanglu Chen; Letao Bo; Zhe-Sheng Chen
Journal:  Mol Biomed       Date:  2021-09-10

Review 8.  Managing Cancer Drug Resistance from the Perspective of Inflammation.

Authors:  Shuaijun Lu; Yang Li; Changling Zhu; Weihua Wang; Yuping Zhou
Journal:  J Oncol       Date:  2022-09-19       Impact factor: 4.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.